Recombinant hu-man soluble thrombomodulin (rhTM) can increase the expression of Glypcan1 and reduce the levels of inflammatory factors in the serum, improve cardiac microcirculation disorder and vascular injury caused by sepsis, and enhance the 48 h survival rate of lipopolysaccharide (LPS)-induced sepsis mouse models. The gene discussed is THBD; the disease is Sepsis.